In multiple pre-clinical models of substance abuse and anxiety, ALDH2 inhibition prevents dopamine surge without changes to basal dopamine levels, and

  • Prevents substance relapse
  • Reduces binge eating
  • Reduces anxiety

ALDH2 Inhibition: Published Pre-Clinical Efficacy Data

ANS-6637 is a Phase-2 ready first-in-class compound that utilizes a novel pathway for the treatment of addiction.

 

ANS-6637 is highly selective ALDH2 Inhibitor that modifies dopaminergic tone by preventing pathophysiologic dopamine surges and associated craving without changes to basal dopamine. This profile, which prevents craving and drug seeking behavior, has the potential to be used as pharmacotherapy for substance and behavior and based addictions.

MOA published in Nature Medicine

ALDH2 inhibition prevents pathophysiologic dopamine surges and associated craving without changes to basal dopamine

ALDH2 Inhibition: Published Neurobiologic Model of Addiction and Mechanism of Action  

  • ALDH2 receptor research started at Harvard
  • CVT synthesized initial compounds (2009 Gilead acquires CVT)
  • Gilead invented GS-6637 (ANS-6637), a highly selective and reversible ALDH2-inhibitor
  • IP thru 2032+
  • Comprehensive manufacturing process and pre-clinical development
  • Preclinical efficacy in gold standard models of addiction relapse, anxiety and binge eating
  • Clinical data from 3 Phase-1 studies in 95 human subjects (2013-2015)
  • ANS-6637 Phase-2 Ready

DEVELOPEMENT HISTORY

Dopamine surge is common to all substance and behavioral addiction

“Environmental stimuli elicit surges of dopamine that trigger craving”